The effect of changing thrombolytic treatment for acute ischemic stroke on healthcare resource usage from the perspective of healthcare professionals: a pilot study
Year: 2025
Type: article
Abstract: OBJECTIVE: This study aimed to investigate the potential impact of replacing alteplase with a single-bolus fibrinolytic agent, such as tenecteplase, on patient care, secondary care management and resource utilization, from the perspective of healthcare professionals practicing within Acute and Comprehensive Stroke Centers across the UK. METHODS: Semi-structured interviews were conducted to gather insights from UK-based healthcare professionals (HCPs) with experience in the administration of thrombolytic treatment or the care of acute ischemic stroke patients within the six months prior to the study initiation. Participants shared their perspective on the potential impact of transitioning to a theoretical single bolus fibrinolytic agent. RESULTS: Six HCPs participated in the study. All agreed that the introduction of a single-bolus thrombolytic agent could save significant stroke specialist nurse time. Participants also noted potential resource use savings, stemming from reduced use of consumables and equipment. Additionally, participants believed that the new agent was likely to improve clinical outcomes and patient wellbeing. CONCLUSION: The introduction of a single-bolus thrombolytic agent to treat acute ischemic stroke could lead to significant system efficiencies in the UK. These findings are expected to be broadly generalizable to other settings and merit global consideration.
Authors: Katie Hayes, George Thomas, Marilena Appierto, Hannah Lorquet
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Boehringer Ingelheim
OpenAlex ID: W4415570953